Neferine inhibits angiotensin II-induced rat aortic smooth muscle cell proliferation predominantly by downregulating fractalkine gene expression

Experimental and Therapeutic Medicine

Volumn 8, Issue 5, 2014, Pages 1545-1550

  Zheng, Lulu ^a   Cao, Yongwen ^a   Liu, Shao ^a   Peng, Zhenyu ^b   Zhang, Saidan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Angiotensin II; Fractalkine; Neferine; Proliferation; Rat aortic smooth muscle cells

Indexed keywords

ANGIOTENSIN II; FRACTALKINE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; NEFERINE; SMALL INTERFERING RNA;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; COUNTER CURRENT CHROMATOGRAPHY; DOWN REGULATION; DRUG MECHANISM; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; NONHUMAN; OPTICAL DENSITY; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RAT; RNA INTERFERENCE; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR SMOOTH MUSCLE CELL; WESTERN BLOTTING;

EID: 84907854133     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1952     Document Type: Article

References (32)

1. Viiri LE, Full LE, Navin TJ, Bequm S, Didangelos A, Astola N, Berge RK, Seppälä I, Shalhoub J, Frankin IJ, Perretti M, Lehtimäki T, Davies AH, Wait R and Monaco C: Smooth muscle cells in human atherosclerosis: proteomic profiling reveals differences in expression of Annexin A1 and mitochondrial proteins in carotid disease. J Mol Cell Cardiol 54: 65-72, 2013.
2. Savoia C, Burger D, Nishigaki N, Montezano A and Touyz RM: Angiotensin II and the vascular phenotype in hypertension. Expert Rev Mol Med 13: e11, 2011.
3. Liu G, Hitomi H, Hosomi N, Lei B, Pelisch N, Nakano D, Kiyomoto H, Ma H and Nishiyama A: Mechanical stretch potentiates angiotensin II-induced proliferation in spontaneously hypertensive rat vascular smooth muscle cells. Hypertens Res 33: 1250-1257, 2010.
4. Kasal DA and Schiffrin EL: Angiotensin II, aldosterone, and anti-inflammatory lymphocytes: interplay and therapeutic opportunities. Int J Hypertens 2012: 829786, 2012.
5. Touyz RM and Schiffrin EL: Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 52: 639-672, 2000.
6. Eguchi S, Dempsey PJ, Frank GD, Motley ED and Inagami T: Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem 276: 7957-7962, 2001.
7. Shi R, Hu C, Yuan Q, Yang T, Peng J, Li Y, Bai Y, Cao Z, Cheng G and Zhang G. Involvement of vascular peroxidase 1 in angiotensin II-induced vascular smooth muscle cell proliferation. Cardiovasc Res 91: 27-36, 2011.
8. Zhao Y, Liu J, Li L, Liu L and Wu L: Role of Ras/PKCzeta/MEK/ERK1/2 signaling pathway in angiotensin II-induced vascular smooth muscle cell proliferation. Regul Pept 128: 43-50, 2005.
9. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A and Schall TJ: A new class of membrane-bound chemokine with a CX3C motif. Nature 385: 640-644, 1997.
10. Balabanian K, Foussat A, Dorfmüller P, Durand-Gasselin I, Capel F, Bouchet-Delbos L, Portier A, Marfaing-Koka A, Krzysiek R, Rimaniol AC, Simonneau G, Emilie D and Humbert M: CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 165: 1419-1425, 2002.
11. Schäfer A, Schulz C, Fraccarollo D, Tas, P, Leutke M, Eigenthaler M, Seidl S, Heider P, Ertl G, Massberg S and Bauersachs J: The CX3C chemokine fractalkine induces vascular dysfunction by generation of superoxide anions. Arterioscler Thromb Vasc Biol 27: 55-62, 2007.
12. Xuan W, Liao Y, Chen B, Huang Q, Xu D, Liu Y, Bin J and Kitakaze M: Detrimental effect of fractalkine on myocardial ischaemia and heart failure. Cardiovasc Res 92: 385-393, 2011.
13. Sullivan JC, Pardieck JL, Doran D, Zhang Y, She JX and Pollock JS: Greater fractalkine expression in mesenteric arteries of female spontaneously hypertensive rats compared with males. Am J Physiol Heart Circ Physiol 296: H1080-H1088, 2009.
14. Perros F, Dorfmüller P, Souza R, Durand-Gasselin I, Godot V, Capel F, Adnot S, Eddahibi S, Mazmanian M, Fadel E, Hervé P, Simonneau G, Emilie D and Humbert M: Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. Eur Respir J 29: 937-943, 2007.
15. Chandrasekar B, Mummidi S, Perla RP, Bysani S, Dulin NO, Liu F and Melby PC: Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway. Biochem J 373: 547-558, 2003.
16. Rius C, Piqueras L, González-Navarro H, Albertos F, Company C, López-Ginés C, Ludwig A, Blanes JI, Morcillo EJ and Sanz MJ: Arterial and venous endothelia display differential functional fractalkine (CX3CL1) expression by angiorensin-II. Arterioscler Thromb Vasc Biol 33: 96-104, 2013.
17. Zhao L, Wang X, Chang Q, Xu J, Huang Y, Guo Q, Zhang S, Wang W, Chen X and Wang J: Neferine, a bisbenzylisoquinline alkaloid attenuates bleomycin-induced pulmonary fibrosis. Eur J Pharmcol 627: 304-312, 2010.
18. Pan Y, Cai B, Wang K, Wang S, Zhou S, Yu X, Xu B and Chen L: Neferine enhances insulin sensitivity in insulin resistant rats. J Ethnopharmacol 124: 98-102, 2009.
19. Lalitha G, Poornima P, Archanah A and Padma VV: Protective effect of neferine against isoproterenol-induced cardiac toxicity. Cardiovasc Toxicol 13: 168-179, 2013.
20. Ho HH, Hsu LS, Chan KC, Chen HM, Wu CH and Wang CJ: Extract from the leaf of nucifera reduced the development of atherosclerosis via inhibition of vascular smooth muscle cell proliferation and migration. Food Chem Toxicol 48: 159-168, 2010.
21. Li XC, Tong GX, Zhang Y, Liu SX, Jin QH, Chen HH and Chen P: Neferine inhibits angiotensin II-stimulated proliferation in vascular smooth muscle cells through heme oxygenase-1. Acta Pharmacol Sin 31: 679-686, 2010.
22. Liu S, Wang B, Li XZ, Qi LF and Liang YZ: Preparative separation and purification of liensinine, isoliensinine and neferine from seed embryo of Nelumbo nucifera GAERTN using high-speed counter-current chromatography. J Sep Sci 32: 2476-2481, 2009.
23. Ludwig A, Berkhout T, Moores K, Groot P and Chapman G: Fractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activity. J Immunol 168: 604-612, 2002.
24. Lucas AD, Bursill C, Guzik TJ, Sadowski J, Channon KM and Greaves DR: Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation 108: 2498-2504, 2003.
25. Ikejima H, Imanishi T, Tsujioka H, Kashiwagi M, Kuroi A, Tanimoto T, Kitabata H, Ishibashi K, Komukai K, Takeshita T and Akasaka T: Upregulation of fractalkine and its receptor, CX3CR1, is associated with coronary plaque rupture in patients with unstable angina pectoris. Circ J 74: 337-345, 2010.
26. Flierl U and Schäfer A: Fractalkine - a local inflammatory marker aggravating platelet activation at the vulnerable plaque. Thromb Haemost 108: 457-463, 2012.
27. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ and Yoshie O: Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91: 521-530, 1997.
28. Damås JK, Boullier A, Waehre T, Smith C, Sandberg WJ et al: Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy. Arterioscler Thromb Vasc Biol 25: 2567-2572, 2005.
29. Stolla M, Pelisek J, von Brühl ML, Schäfer A, Barocke V, Heider P, Lorenz M, Tirniceriu A, Steinhart A, Bauersachs J, Bray PF, Massberg S and Schulz C: Fractalkine is expressed in early and advanced atherosclerotic lesions and supports monocyte recruitment via CX3CR1. PLoS One 7: e43572, 2012.
30. Combadière C, Potteaux S, Gao JL, Esposito B, Casanova S et al: Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 107: 1009-1016, 2003.
31. Lesnik P, Haskell CA and Charo IF. Decreased atherosclerosis in CX3CR1-/-mice reveals a role for fractalkine in atherogenesis. J Clin Invest 111: 333-340, 2003.
32. Cheng JF, Ni GH, Chen MF, Li YJ, Wang YJ, Wang CL, Yuan Q, Shi RZ, Hu CP and Yang TL: Involvement of profilin-1 in angiotensin II-induced vascular smooth muscle cell proliferation. Vascul Pharmacol 55: 34-41, 2011.